1059.6000 6.00 (0.57%)
NSE Sep 04, 2026 15:31 PM
Volume: 217.2K
 

1059.60
0.57%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma has gained 24.56% in the last 6 Months
More from Strides Pharma Science Ltd.
Recommended